Last reviewed · How we verify
Capecitabine, Tarceva
At a glance
| Generic name | Capecitabine, Tarceva |
|---|---|
| Also known as | Capecatine, Xeloda, Tarceva, Erlotinib, OSI-774 |
| Sponsor | Milton S. Hershey Medical Center |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery (PHASE3)
- Gemcitabine, Capecitabine, and Erlotinib in Treating Patients With Advanced Pancreatic Cancer (PHASE1)
- Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial (PHASE1)
- Chemotherapy Plus Proton-chemotherapy for Locally Advanced Pancreatic Cancer (NA)
- ChemoRT With Adjuvant Chemo in Pancreatic Cancer (TARCEVA) (PHASE2)
- Carbon Ion Radiation Therapy for Locally Advanced Pancreatic Cancer (PHASE1)
- Individualized Drug Treatment for Treating Patients With Pancreatic Cancer (PHASE2)
- Safety and Efficacy of Combination Listeria/GVAX Pancreas Vaccine in the Pancreatic Cancer Setting (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Capecitabine, Tarceva CI brief — competitive landscape report
- Capecitabine, Tarceva updates RSS · CI watch RSS
- Milton S. Hershey Medical Center portfolio CI